Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 31.9% in December

Xilio Therapeutics, Inc. (NASDAQ:XLO) saw a large drop in short interest in December. As of December 15th, there was short interest totalling 119,400 shares, a drop of 31.9% from the November 30th total of 175,300 shares. Based on an average daily volume of 424,600 shares, the short-interest ratio is currently 0.3 days. Currently, 0.6% of the shares of the company are sold short.

Xilio Therapeutics Stock Down 0.3 %

Xilio Therapeutics stock opened at $0.97 on Monday. The stock has a 50-day moving average price of $1.04 and a 200 day moving average price of $0.93. The company has a market capitalization of $42.74 million, a price-to-earnings ratio of -0.57 and a beta of -0.29. Xilio Therapeutics has a 52 week low of $0.50 and a 52 week high of $1.93.

Institutional Trading of Xilio Therapeutics

Large investors have recently made changes to their positions in the business. XTX Topco Ltd purchased a new stake in Xilio Therapeutics in the 2nd quarter worth approximately $32,000. Renaissance Technologies LLC increased its holdings in Xilio Therapeutics by 18.3% in the 2nd quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock worth $280,000 after acquiring an additional 45,554 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Xilio Therapeutics by 85.0% during the third quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock worth $266,000 after acquiring an additional 155,337 shares during the period. 54.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Raymond James dropped their price objective on shares of Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a report on Friday, November 8th.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.